scholarly journals Present and Future of Endoscopic Ultrasound-Guided Tissue Acquisition in Solid Pancreatic Tumors

2019 ◽  
Vol 52 (6) ◽  
pp. 541-548
Author(s):  
Jae Keun Park ◽  
Kwang Hyuck Lee
2019 ◽  
Vol 89 (6) ◽  
pp. AB295
Author(s):  
Emmanuel Coronel ◽  
Hamzah Abu-Sbeih ◽  
Irina M. Cazacu ◽  
Phillip Lum ◽  
Victor Garcia Rodriguez ◽  
...  

2018 ◽  
Vol 4 (1) ◽  
pp. 75-80 ◽  
Author(s):  
Zhigang Song ◽  
Charles N. Trujillo ◽  
Helen Song ◽  
Jane E. Tongson-Ignacio ◽  
Michael Y. Chan

Endoscopy ◽  
2020 ◽  
Author(s):  
Dongwook Oh ◽  
Sung Woo Ko ◽  
Dong-Wan Seo ◽  
Seung-Mo Hong ◽  
Jin Hee Kim ◽  
...  

Abstract Background Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been increasingly used for the management of various solid pancreatic tumors. This study aimed to evaluate the feasibility and safety of EUS-RFA for serous cystic neoplasms (SCNs). Methods 13 patients with microcystic SCNs with honeycomb appearance underwent EUS-RFA using a 19-gauge RFA needle. Before ablation, cystic fluid was aspirated until a thin layer of fluid remained. Results EUS-RFA was successful in all patients. Seven patients underwent a single session and the remaining six patients underwent a second session of EUS-RFA. One patient (7.7 %) experienced self-limited abdominal pain after EUS-RFA. During a median follow-up period of 9.21 months (interquartile range [IQR] 5.93 – 15.38), the median volume of the SCNs decreased from 37.82 mL (IQR 15.03 – 59.53) at baseline to 10.95 mL (IQR 4.79 – 32.39) at the end of follow-up. A radiologic partial response was achieved in eight patients (61.5 %). Conclusions EUS-RFA is technically feasible and showed an acceptable rate of adverse events for patients with SCNs. A long-term follow-up study is required to evaluate the efficacy of EUS-RFA.


2019 ◽  
Vol 31 (2) ◽  
pp. 146-147 ◽  
Author(s):  
Takuji Iwashita ◽  
Ichiro Yasuda ◽  
Masahito Shimizu

Sign in / Sign up

Export Citation Format

Share Document